Fungal Frontiers: Expert Decision Making in Medical Mycology

Released On
June 15, 2018

Expires On
June 14, 2019

Media Type
Internet

Completion Time
120 minutes

Specialty
Infectious diseases, hospital medicine, hematology/oncology, pathology, medical microbiology, critical care, pharmacy, and surgery

Topic(s)
Mycology

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by University of Nebraska Medical Center, Center for Continuing Education; Terranova Medica, LLC; and the Mycoses Study Group Educational and Research Consortium.

 

This activity is supported in part by an independent education grant from Astellas; Merck & Co, Inc.; and Gilead Sciences Europe, Ltd.

Credit Available

  • Physicians — maximum of 2.0 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is directed to specialists in infectious diseases, hospital medicine, hematology/oncology, pathology, medical microbiology, critical care, pharmacy, and surgery, as well as other healthcare providers responsible for the management of invasive mycoses.

Program Overview

This activity, Fungal Frontiers: Expert Decision Making in Medical Mycology, is designed to evaluate different approaches to managing clinical scenarios at the frontiers of invasive fungal infections. A series of cases will offer the opportunity to explore the levels of evidence behind different strategies, contrasting expert decision making with that of the broader audience, and evaluating the emerging research for each clinical “frontier.” Specific content on Candida auris infection, antifungal prophylaxis in an HSCT patient, and management of refractory molds will be provided.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Define the role of emerging diagnostics in the management of invasive fungal disease (IFD)
  • Discuss epidemiologic/resistance trends having an impact on IFD management
  • Choose appropriate antifungal therapeutics, with an eye toward pharmacologic optimization

Faculty

Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA, CMQ

Professor of Medicine and Epidemiology
Director, Mycology Research Laboratory
University of Texas Medical School at Houston
Houston, Texas

Melissa D. Johnson, PharmD, MHS, AAHIVP

Liaison Clinical Pharmacist for Duke Antimicrobial Stewardship Outreach Network
Associate Professor of Medicine
Division of Infectious Diseases
Duke University Medical Center
Durham, North Carolina

Jose A. Vazquez, MD, FACP, FIDSA

Chief, Division of Infectious Diseases and Professor of Medicine
Medical College of Georgia
Augusta University
Augusta, Georgia

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education; Terranova Medica, LLC; and the Mycoses Study Group Educational and Research Consortium.

Credit Designation

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA, CMQ

  • Research support from Astellas; Cidara; Pfizer, Inc.; Scynexis
  • Advisory board fees from Cidara; Merck & Co., Inc.; Pfizer; Scynexis
  • Consultant fees from Aradigm; Astellas; Bayer
  • Speakers bureau honorarium from Gilead; Merck & Co., Inc.; Pfizer, Inc.

Melissa D. Johnson, PHARMD, MHS, AAHIVP

  • Research support from Charles River Laboratories; Merck & Co., Inc.
  • Royalty fees from UpToDate

Jose A. Vazquez, MD, FACP, FIDSA

  • Research support from Astellas
  • Advisory board fees from Cidara
  • Consultant fees from Cidara; T2 Biosystems

Instructions for Participation and Credit

During the period June 15, 2018 through June 14, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the posttest and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Submit Posttest at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 75% or higher), your Statement of Participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 75%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
There are no fees for participating and receiving CME credit for this enduring activity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For CME questions, please contact: Tom Davis by telephone/fax (877-276-4523) or email (tdavis@terranovamedica.com).

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade) and program evaluation. Certificates can be printed immediately.

Hardware and Software Requirements

Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclaimer

The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the facult. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure of Unlabeled Use

The University of Nebraska Medical Center, Center for Continuing Education requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. Dr Ostrosky-Zeicnher will have a discussion of investigational agents and diagnostics for antifungals in difficult cases.
Dr Johnson has a discussion of fluconazole, voriconazole, and isavuconazole as potential options for antifungal prophylaxis, although these agents do not have an FDA indication for this use.